Zobrazeno 1 - 10 of 540 pro vyhledávání: '"McGlinchey K"'
1
Report
Burn regimes in the hydrodynamic scaling of perturbed inertial confinement fusion hotspots
Autor: Tong, J. K., McGlinchey, K., Appelbe, B. D., Walsh, C. A., Crilly, A. J., Chittenden, J. P.
We present simulations of ignition and burn based on the Highfoot and High-Density Carbon indirect drive designs of the National Ignition Facility for three regimes of alpha-heating - self-heating, robust ignition and propagating burn - exploring hot
Externí odkaz: http://arxiv.org/abs/1902.05861
Zobrazit plný text záznamu
3
Akademický článek
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
Autor: Zanvit P; Early Oncology Research., van Dyk D; Biologics Engineering., Fazenbaker C; Early Oncology Research., McGlinchey K; Early Oncology Research., Luo W; Early Oncology Research., Pezold JM; Early Oncology Research., Meekin J; Early Oncology Research., Chang CY; Biologics Engineering., Carrasco RA; Early Oncology Research., Breen S; Early Oncology Research., Cheung CS; Biologics Engineering., Endlich-Frazier A; Biologics Engineering., Clark B; Biologics Engineering., Chu NJ; Early Oncology Research., Vantellini A; Discovery Sciences, Oncology R&D, and., Martin PL; Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Hoover CE; Clinical Pathology Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Riley K; Clinical Pathology Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Sweet SM; Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Chain D; Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Kim YJ; Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Tu E; Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Harder N; Computational Pathology, AstraZeneca, Munich, Germany., Phipps S; Biologics Engineering., Damschroder M; Biologics Engineering., Gilbreth RN; Biologics Engineering., Cobbold M; Early Oncology Research., Moody G; Early Oncology Research., Bosco EE; Early Oncology Research.
Publikováno v: The Journal of clinical investigation [J Clin Invest] 2023 Nov 15; Vol. 133 (22). Date of Electronic Publication: 2023 Nov 15.
Zobrazit plný text záznamu
4
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire
Autor: Swanson, PA, Padilla, M, Hoyland, W, McGlinchey, K, Fields, PA, Bibi, S, Faust, SN, McDermott, AB, Lambe, T, Pollard, AJ, Durham, NM, Kelly, EJ, AstraZeneca/Oxford/VRC Study Group, Adlou, S, Aley, PK, Angus, B, Anslow, R, Baker, P, Bansal, H, Beveridge, A, Bridges-Webb, A, Ching, S, Cicconi, P, Clutterbuck, EA, Collins, AM, Darton, TC, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Ewer, KJ, Felle, S, Ferreira, DM, Folegatti, PM, Fuskova, M, Gaudinski, M, Gilbert, SC, Goodman, AL, Gordon, I, Green, CA, Harbolick, E, Hayes, S, Hill, AVS, Hill, H, Jenkin, D, Jepson, BM, Kasanyinga, M, Libri, V, Lillie, PJ, McGregor, AC, Minassian, AM, Mujadidi, YF, Novik, L, Payne, R, Pilataxi, F, Plested, E, Provstgaard-Morys, S, Ramasamy, M, Robinson, H, Sanders, K, Smith, A, Snape, MD, Song, R, Sutherland, RK, Thomson, EC, Toshner, M, Turner, DPJ, Voysey, M, Widge, AT, Williams, CJ
AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::993e6e80c4502ef8c2b6b487068309ee
https://eprints.whiterose.ac.uk/178925/1/scitranslmed.abj7211.pdf
Zobrazit plný text záznamu
5
Akademický článek
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Autor: Goldman JW; Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas, Maryland Anderson Cancer Center, Houston, Texas., Curti B; Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon., Pedersen KS; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee., Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York., Chhaya V; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., Kirby G; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., McGlinchey K; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., Hammond SA; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., Streicher K; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., Townsley DM; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland., Chae YK; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois., Voortman J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands., Marabelle A; Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), INSERM U1015 & CIC1428, Gustave Roussy, Université Paris Saclay, Villejuif, France., Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Sep 01; Vol. 28 (17), pp. 3709-3719.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Autor: Tu E; Translational Medicine and., McGlinchey K; Research Early Oncology, AstraZeneca, Gaithersburg, Maryland, USA., Wang J; Translational Medicine and., Martin P; Translational Medicine and., Ching SL; Translational Medicine and., Floc'h N; Oncology R&D, Bioscience, AstraZeneca, Cambridge, United Kingdom., Kurasawa J; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA., Starrett JH; Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Lazdun Y; Translational Medicine and., Wetzel L; Research Early Oncology, AstraZeneca, Gaithersburg, Maryland, USA., Nuttall B; Translational Medicine and., Ng FS; Translational Medicine and., Coffman KT; Alliance Management, AstraZeneca, Gaithersburg, Maryland, USA., Smith PD; Oncology R&D, Bioscience, AstraZeneca, Cambridge, United Kingdom., Politi K; Department of Pathology and Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA., Cooper ZA; Translational Medicine and., Streicher K; Translational Medicine and.
Publikováno v: JCI insight [JCI Insight] 2022 Feb 08; Vol. 7 (3). Date of Electronic Publication: 2022 Feb 08.
Zobrazit plný text záznamu
10
Akademický článek
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T H 1 response with a diverse TCR repertoire.
Autor: Swanson PA 2nd; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Padilla M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Hoyland W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., McGlinchey K; Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Fields PA; Adaptive Biotechnologies, Seattle, WA 98102, USA., Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford OX4 6PG, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, UK., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Lambe T; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford OX3 7FZ, UK., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford OX4 6PG, UK., Durham NM; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Kelly EJ; Translational Medicine, Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
Publikováno v: Science translational medicine [Sci Transl Med] 2021 Nov 17; Vol. 13 (620), pp. eabj7211. Date of Electronic Publication: 2021 Nov 17.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje